Respiratory disease

30 Technology’s Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications

Retrieved on: 
Wednesday, April 19, 2023
Infection, COPD, Social work, LSE, Research and development, Therapy, Powder, CTEC, Stifel, Respiratory disease, Nitric oxide, Health, Immunity, Research, Cystic fibrosis, National Institute of General Medical Sciences, IP, Fungus, Sale, CN v Secretary of State for Health and Social Care, Divestment, NO, Patent, Patient, Ophthalmology, Convatec, Bacteria, NHS, Burns, Rare, Scottish Enterprise, Virus, Dentistry, Pharmaceutical industry, Vaccine, Bronchiectasis

London, UK, 19 April 2023 – 30 Technology, the world leader in clinical nitric oxide generation technology for health care, today announced that it has completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc (LSE: CTEC).

Key Points: 
  • London, UK, 19 April 2023 – 30 Technology, the world leader in clinical nitric oxide generation technology for health care, today announced that it has completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc (LSE: CTEC).
  • As part of the transaction, a small team from 30 Technology will transfer across to Convatec.
  • Syd Hanna, Group Executive Director of 30 Technology commented: “This transaction validates 30 Technology’s transformational approach to unlock the potential of nitric oxide to treat a range of infections with a durable and safe treatment.
  • Stifel acted as financial advisor and Goodwin Procter provided legal counsel to 30 Technology.

Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent

Retrieved on: 
Tuesday, April 18, 2023
Madagascar, COPD, Patent, RTI, COVID-19, Respiratory disease, United States patent law, CBM, Respiratory syncytial virus, Nose, Rhinovirus, RSV, Patient, Coronavirus, Viral, Disease, Vaccine, Pharmaceutical industry

Neumifil, Pneumagen’s lead product, is being developed for the broad-spectrum prevention of viral induced exacerbations including those caused by influenza virus (IFV), respiratory syncytial virus (RSV), rhinovirus and coronavirus infections including COVID-19.

Key Points: 
  • Neumifil, Pneumagen’s lead product, is being developed for the broad-spectrum prevention of viral induced exacerbations including those caused by influenza virus (IFV), respiratory syncytial virus (RSV), rhinovirus and coronavirus infections including COVID-19.
  • Neumifil is currently being evaluated in a Phase 2a proof of concept challenge study in healthy participants subsequently infected with influenza virus.
  • Douglas Thomson, CEO of Pneumagen, commented: “This US patent grant is a key milestone for Pneumagen, which builds further significant value for Neumifil, our novel first in class host cell-targeted antiviral.
  • We are continuing to make excellent progress in developing this lead product and look forward to seeing further results from our clinical programme.

ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

Retrieved on: 
Monday, April 17, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, 23andMe, GSK plc, Royal Brompton Hospital, Asthma, Drug development, MBBS, Therapy, SORT, Doctor of Philosophy, Bias, MBA, Recode, Inflammation, Messenger, Pulmonology, Novartis, Lane, Patient, Respiratory disease, Cystic fibrosis, Hospital, LNP, Biomarker, Pharmacology, Imperial College London, MRCP, Disease, Medical device, Pharmaceutical industry, Genentech

ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.
  • Dr. Matthews will oversee clinical development planning and strategy.
  • “We are delighted to welcome Dr. Matthews to build and lead our clinical team,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics.
  • He spent the previous ten years at Genentech, a subsidiary of Roche, in leadership roles including senior group medical director.

NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors

Retrieved on: 
Monday, April 3, 2023
Pharma, Respiratory disease, Cardiovascular disease, NAMS, Research, Apolipoprotein, Sacubitril/valsartan, Neuroscience, Dermatology, Novartis, INSEAD, Patient, Ophthalmology, Pain management, Utrecht University, Pharmaceutical industry, Chemistry

NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the appointment of Janneke van der Kamp as an independent director to its Board of Directors.

Key Points: 
  • NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the appointment of Janneke van der Kamp as an independent director to its Board of Directors.
  • Ms. van der Kamp is an established pharmaceutical leader, with two decades of experience launching and growing key brands across several therapeutic areas, including cardiovascular disease.
  • Ms. van der Kamp holds an M.B.A. from INSEAD and an M.S.
  • “I am thrilled to join NewAmsterdam’s Board of Directors,” said Ms. van der Kamp.

Direct Biologics Announces FDA Authorization to Expand Ongoing Phase 3 Clinical Study of ExoFlo™ to All-Cause Moderate-to-Severe ARDS

Retrieved on: 
Tuesday, April 4, 2023
Research, Medical Devices, Clinical Trials, Health Technology, Stem Cells, Other Health, Biotechnology, Health, Science, Other Science, Respiratory disease, Survival, Regenerative Medicine Advanced Therapy, Inflammation, Regenerative medicine, EVS, Seminal vesicles, Patient, Acute respiratory distress syndrome, Mortality, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry

In addition, the trial will evaluate the efficacy of ExoFlo in ARDS subtypes to better understand the disease process.

Key Points: 
  • In addition, the trial will evaluate the efficacy of ExoFlo in ARDS subtypes to better understand the disease process.
  • In March 2022, ExoFlo received Regenerative Medicine Advanced Therapy, or RMAT, designation by the FDA, which provides opportunities to expedite ExoFlo’s clinical development for ARDS.
  • “FDA authorization to expand our ongoing Phase 3 clinical trial to all-cause ARDS marks a defining moment for regenerative medicine.
  • In fact, ExoFlo is one of a small handful of biologics that has demonstrated adequate tolerability and clinical activity to gain allowance by the FDA for Phase 3 evaluation in moderate-to-severe ARDS,” said Amy Lightner, M.D., Chief Medical Officer of Direct Biologics.

Chiesi's international growth continues

Retrieved on: 
Wednesday, April 5, 2023
China Biologic Products, Benefit corporation, B Lab, Respiratory disease, European Patent Office, EPO, EBITDA, Sustainability, Investment, European Patent Convention, Growth, B Corporation (certification), Environment, Fine chemical, Pharmaceutical industry, Chiesi Farmaceutici

It has a solid positive net financial position of €1,390 million, €342 million more than previous year.

Key Points: 
  • It has a solid positive net financial position of €1,390 million, €342 million more than previous year.
  • A commitment that I share, together with the Chiesi family, and that will drive us into the next stages of international growth."
  • Research growth is mainly driven by partnerships and collaborations (Allinaire Therapeutics, Aptar Digital health, Kaia Health) and acquisitions (Amryt).
  • In July 2022, Chiesi – a Benefit Corporation in Italy (Società Benefit), the United States and France (Société à Mission) – achieved B Corp recertification by international non-profit organisation B Lab.

Chiesi's international growth continues

Retrieved on: 
Wednesday, April 5, 2023
China Biologic Products, Benefit corporation, B Lab, Respiratory disease, European Patent Office, EPO, EBITDA, Sustainability, Investment, European Patent Convention, Growth, B Corporation (certification), Environment, Fine chemical, Pharmaceutical industry, Chiesi Farmaceutici

It has a solid positive net financial position of €1,390 million, €342 million more than previous year.

Key Points: 
  • It has a solid positive net financial position of €1,390 million, €342 million more than previous year.
  • A commitment that I share, together with the Chiesi family, and that will drive us into the next stages of international growth."
  • Research growth is mainly driven by partnerships and collaborations (Allinaire Therapeutics, Aptar Digital health, Kaia Health) and acquisitions (Amryt).
  • In July 2022, Chiesi – a Benefit Corporation in Italy (Società Benefit), the United States and France (Société à Mission) – achieved B Corp recertification by international non-profit organisation B Lab.

New Screening Technology Can Help Implement PACT Act--Aid Veterans Suffering Burn Pit Exposure

Retrieved on: 
Thursday, March 23, 2023
COPD, Asthma, Capitol Hill, PACT Act, Respiratory disease, Honoring our PACT Act of 2022, XV, Burn, Cancer, Veteran, Bronchiolitis, Lung, Ventilation, Hauser, Address, Chronic obstructive pulmonary disease, PACT, Congress, Physician, United States Department of Veterans Affairs, 4D, Cystic fibrosis, Sergeant, Air force, United States Department of the Air Force, FDA, Disease, Medical imaging

WASHINGTON, March 23, 2023 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, made the rounds on Capitol Hill Wednesday urging lawmakers to harness the latest emerging technologies to treat veterans suffering from exposure to toxic burn pits. 4D is asking Congress to allocate funds for a pilot program to implement their non-invasive lung screening technology at 3–5 U.S. Department of Veterans Affairs (VA) sites around the country.

Key Points: 
  • 4D is asking Congress to allocate funds for a pilot program to implement their non-invasive lung screening technology at 3–5 U.S. Department of Veterans Affairs (VA) sites around the country.
  • Hensley, Hauser and Le Roy Torres have recently received a scan using 4D's imaging technology.
  • "Passing the PACT Act was a major milestone, but its potential is only as good as the VA's ability to implement it.
  • 4DMedical technology is providing clinicians with greater insights into lung function and the impact of diseases and treatment interventions.

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Tuesday, March 21, 2023
EUA, ITAP, Heart failure, Diabetes, Marketing, COVID-19, Respiratory disease, Research, COVID, Inflammation, Bangladesh Technical Education Board, Platform, Webcast, POC, FDA, NIH, Cryptocurrency, Video game, Medical device, Pharmaceutical industry

LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022.

Key Points: 
  • LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022.
  • For the three months ended December 31, 2022, LumiraDx delivered revenue of $41.1 million compared to $42.2 million for the third quarter of 2022 and $118.3 million for the fourth quarter of 2021.
  • Covid antigen test revenues for the quarter were $24.7 million while our Fast Labs Covid revenues were $8.0 million in the fourth quarter of 2022.
  • In the fourth quarter of 2022 and for the full year 2022, our test strip margin continued to exceed 80%.

New American Lung Association Research Institute to Accelerate High Impact, Lifesaving Lung Health Science

Retrieved on: 
Tuesday, March 21, 2023
COPD, Tobacco Products Scientific Advisory Committee, Pulmonary Vascular Research Institute, Partnership, Asthma, American Lung Association, COVID-19, Lung cancer, Research, Government, Press release, Canadian Lung Association, Respiratory disease, Research institute, Health, Death, National Board of Health and Welfare (Sweden), Pharmaceutical industry

CHICAGO, March 21, 2023 /PRNewswire/ -- More than 34 million Americans live with lung disease. When combined with lung cancer and respiratory diseases like COVID-19 and influenza, lung disease is a leading cause of death in America. To address urgent and critical lung health challenges in our country, the American Lung Association today announced the launch of the American Lung Association Research Institute.

Key Points: 
  • To address urgent and critical lung health challenges in our country, the American Lung Association today announced the launch of the American Lung Association Research Institute .
  • The American Lung Association Research Institute is our answer to this challenge, and we are committed to investing in research, collaborating with experts and empowering scientists to accelerate discovery and innovation," said Harold Wimmer, President and CEO of the American Lung Association.
  • "The Lung Association has long been the trusted champion of lung health research, and the new Research Institute will take our work to end lung disease to the next level."
  • The new American Lung Association Research Institute will:
    Increase Research Investment through the organization's Awards and Grants program to $25 million per year by 2030.